Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

12548

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Parkinson Disease
Interventions: AP-472, Placebo; Drug · Other
Lead sponsor: Appello Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more

Conditions: Generalized Myasthenia Gravis
Interventions: Pozelimab + Cemdisiran, Cemdisiran, Placebo, Pozelimab; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 19
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 16 more

Conditions: Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Iadademstat; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 32
States / cities: Irvine, California • Orange, California • Palo Alto, California + 28 more

Conditions: Cerebral Aneurysm
Interventions: Microsurgical clipping, Endovascular treatment, Sirolimus; Procedure · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: GSK4532990; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Chula Vista, California • Montclair, California • San Diego, California + 8 more

Conditions: Plaque Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more

Conditions: Ovarian Neoplasms
Interventions: CleoDX ovarian cancer test; Diagnostic Test
Lead sponsor: Cleo Diagnostics Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: Chandler, Arizona • Jacksonville, Florida • Miami, Florida + 15 more

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 136
States / cities: Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 115 more

Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 365 Days
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 116
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more

Conditions: Geographic Atrophy, Macular Degeneration
Interventions: Avacincaptad pegol (ACP); Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: Not listed
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more

Conditions: Diabetic Kidney Disease (DKD)
Interventions: ALN-ANG3, Evinacumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 59
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 366 Days to 46 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 145
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more

Clinical trials in Miami, Florida

Filter and sort this location

Live official records

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)